Based on two different types of luminescence systems (Ru﹡(bpy)₃²⁺/TPA and SnO₂ NFs/K₂S₂O₈), a new type of electrochemiluminescence (ECL) immunosensor was prepared, which realized the detection of acute myocardial infarction biomarker cTnI. In this strategy, Ru(bpy)₃²⁺, above all, was immobilized on the NH₂-MIL-125 as a capture probe. Subsequently, cTnI and SnO₂ NFs was bonded to the electrode surface through the interaction between antigen and antibody in turn. During this process, Ru(bpy)₃²⁺ and the co-reactant TPA first showed strong and stable ECL emission. As the concentration of cTnI in the test system increased, the signal of SnO₂ NFs and the co-reactant K₂S₂O₈ gradually enhanced, indicating self-calibrating mechanism of the assay system. Therefore, the "off-on" ECL immunosensor can be detected in the linear range of 10^-5 -10⁴ ng/mL, and the LOD limit of detection (LOD) is 3.39 fg/mL (S/N=3), respectively. The dual-signal electrochemiluminescence method has the advantages of low cost, simple analysis process, wide detection range and good selectivity, providing a promising analysis protocol for clinical applications.

基于两种不同类型的发光体系（Ru﹡(bpy) ₃ ²⁺ /TPA 和SnO ₂ NFs/K ₂ S ₂ O ₈），制备了一种新型的电化学发光（ECL）免疫传感器，实现了急性心肌梗死生物标志物 cTnI。在该策略中，首先将Ru(bpy) ₃ ²⁺固定在NH ₂ -MIL-125 上作为捕获探针。随后，cTnI和SnO ₂ NF依次通过抗原和抗体之间的相互作用结合到电极表面。在这个过程中，Ru(bpy) ₃ ²⁺共反应物TPA首先表现出强而稳定的ECL发射。随着检测体系中cTnI浓度的增加，SnO ₂ NFs和共反应物K ₂ S ₂ O _{8 的信号}逐渐增强，表明检测体系具有自校准机制。因此，“关-开”ECL免疫传感器可以在10 ^-5 -10 ⁴ ng/mL的线性范围内检测到，并且细节层次检测限 (LOD) 分别为 3.39 fg/mL (S/N=3)。双信号电化学发光法具有成本低、分析过程简单、检测范围广、选择性好等优点，为临床应用提供了一种很有前景的分析方案。